CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Real Life Data of Treat and Extend Intravitreal Ranibizumab and Aflibercept Therapy in Wet Age-related Macular Degeneration Patients: 3-Year Results
Ozgul Ugurtay, Alev Kockar, Elvan Alper Sengul
Korean J Ophthalmol. 2021;35(4):280-286.   Published online June 21, 2021
DOI: https://doi.org/10.3341/kjo.2020.0109

Excel Download

Real Life Data of Treat and Extend Intravitreal Ranibizumab and Aflibercept Therapy in Wet Age-related Macular Degeneration Patients: 3-Year Results
Korean Journal of Ophthalmology. 2021;35(4):280-286   Crossref logo
Link1 Link2 Link3

Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia
BMC Ophthalmology. 2018;18(1):   Crossref logo
Link1 Link2 Link3

Comparison of Two Different Treat-and-Extend Protocols with Aflibercept in Wet Age-Related Macular Degeneration: Two-Year Results
Advances in Therapy. 2020;37(5):2256-2266   Crossref logo
Link1 Link2 Link3

Cost-Effectiveness Analysis of Intravitreal Aflibercept Compared with Ranibizumab-Prn in Patients with wet Age-Related Macular Degeneration (Wamd)
Value in Health. 2015;18(7):A880   Crossref logo
Link1 Link2

Development of Age-Related Macular Degeneration (AMD) in the Fellow Eye of Patients with AMD Treated by Treat-and-Extend Intravitreal Therapy with Aflibercept
Ophthalmologica. 2017;239(2-3):121-127   Crossref logo
Link1 Link2

Cost-Minimization Analysis of Intravitreal Aflibercept Compared with Ranibizumab on-Label In Patients with wet Age-Related Macular Degeneration (Wamd)
Value in Health. 2015;18(7):A881   Crossref logo
Link1 Link2

Comparison between Aflibercept, Ranibizumab intravitreal injection on Neovascular Age-related macular degeneration patients
Acta Ophthalmologica. 2016;94:   Crossref logo
Link1 Link2

Comment on ‘Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results’
Eye. 2015;29(12):1630-1630   Crossref logo
Link1 Link2 Link3

Two-Year Outcomes of a Treat-and-Extend Regimen Using Intravitreal Aflibercept Injections for Typical Age-Related Macular Degeneration
Ophthalmologica. 2017;238(4):236-242   Crossref logo
Link1

Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration
Graefe's Archive for Clinical and Experimental Ophthalmology. 2019;257(8):1671-1677   Crossref logo
Link1 Link2 Link3